Abeona therapeutics reports third quarter 2023 financial results and corporate developments

Abeona's first-ever u.s. biologics license application (bla) submission completed in september 2023 fda decision on priority review and acceptance of bla for pz-cel (prademagene zamikeracel, formerly known as eb-101) in recessive dystrophic epidermolysis bullosa (rdeb) expected by late-november 2023 initiated commercial readiness activities for potential u.s. launch of pz-cel cleveland, nov. 13, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today reported financial results for the third quarter of 2023 and provided corporate updates. “in the third quarter, we made substantial progress in our evolution from a late-stage clinical development company to one with significant commercial opportunity,” said vish seshadri, chief executive officer of abeona.
ABEO Ratings Summary
Quant
ABEO Quant Ranking
Sector
Industry
Quant Rating
Quant Score